Abstract
Proliferative vitreoretinopathy (PVR) remains a significant challenge for vitreoretinal surgeons. Its incidence, as a complication of retinal detachment, does not appear to have altered despite improvement in surgical techniques. Extensive laboratory research has been undertaken to investigate the pathogenesis of PVR and the use of adjunctive mediations to modify the disease process. To date these studies have not resulted in improved clinical management of PVR. Previous concepts of the pathogenesis of PVR, focussing on a central role for RPE cells, may be flawed and could potentially have contributed to the lack of clinical advances. Revised clinical classifications and novel approaches to adjunctive treatment may in the future result in improved surgical outcomes.
摘要
增殖性玻璃体视网膜病变 (PVR) 仍是玻璃体视网膜外科医生所面临的重大挑战。由其所导致的视网膜脱离的发病率并未随着手术技术的发展而降低。大量基础研究针对PVR的发病机理进行了深入研究, 各种辅助性药物的应用也试图改变疾病的发展过程。到目前为止, 这些研究并没提高PVR的临床治疗策略。以往对于PVR发病机制的理解, 主要关注于RPE在PVR发病中的重要作用, 目前看来是有缺陷的, 因此对于临床进展的推动作用甚微。改良的临床分类和新的辅助性治疗方法会在未来改善手术的预后
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121–5.
Joeres S, Kirchhof B, Joussen AM. PVR as a complication of rhegmatogeneous retinal detachment: a solved problem? Br J Ophthalmol. 2006;90:796–7.
Heimann H, Bartz-Schmidt KU, Bornfeld N, Weiss C, Hilgers RD, Foerster MH, Scleral Buckling versus Primary Vitrectomy in Rhegmatogenous Retinal Detachment Study Group. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study. Ophthalmology. 2007;114:2142–54.
Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. A randomised controlled trial of combined 5-fluorouracil and low molecular weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114:698–704.
Andenmatten R, Gonvers M. Sophisticated vitreoretinal surgery in patients with a healthy fellow eye. An 11-year retrospective study. Graefes Arch Clin Exp Ophthalmol. 1993;231:495–9.
Lewis H, Aaberg TM, Abrams GW. Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol. 1991;111:8–14.
Lewis H, Aaberg TM. Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol. 1991;111:15–9.
Silicone Study Group. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone study report 2. Arch Ophthalmol. 1992;110:780–92.
Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management and adjunctive treatment. Br J Ophthalmol. 1995;79:953–60.
Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982;94:458–67.
Blumenkranz M, Hernandez E, Ophir A, Norton EW. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology. 1984;91:122–30.
Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy—developments in adjunctive treatment and retinal pathology. Eye. 2002;16:369–74.
Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2016;51:125–55.
Binder S, Bonnet M, Velikay M, Gerard JP, Stolba U, Wedrich A, et al. Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study. Graefes Arch Clin Exp Ophthalmol. 1994;232:211–4.
Williams RG, Chang S, Comaratta MR, Simoni G. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol. 1996;234:496–503.
Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive Daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Am J Ophthalmol. 1998;126:550–9.
Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179–83.
Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RHY, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111:2240–5.
Sethi CS, Lewis GP, Fisher SK, Leitner WP, Mann DL, Luthert PJ, et al. Glial remodelling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Investig Ophthalmol Vis Sci. 2005;46:329–42.
Charteris DG, Downie J, Aylward GW, Sethi C, Luthert P. Intraretinal and periretinal pathology in anterior proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:93–100.
Lewis GP, Chapin EA, Luna G, Linberg KA, Fisher SK. The fate of Müller’s glia following experimental retinal detachment: nuclear migration, cell division, and subretinal glial scar formation. Mol Vis. 2010;16:1361–72.
Charteris DG, Lewis GP, Fisher SK. Triamcinolone reduces intraretinal proliferation in acute experimental retinal detachment. Investig Ophthalmol Vis Sci. 2008;49:4887.
Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal fibrosis–a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol. 1982;219:268–71.
Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005;40:598–604.
Cheema RA, Peyman GA, Fang T, Jones A, Lukaris AD, Lim K. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging. 2007;38:365–70.
Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology. 2008;115:1938–43.
Banerjee PJ, Quartilho A, Bunce C, Xing W, Zvobgo TM, Harris N. et al. Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmology. 2017;124:757–67.
Banerjee PJ, Xing W, Bunce C, Woodcock M, Chandra A, Scott RA, et al. Triamcinolone during pars plana vitrectomy for open globe trauma: a pilot randomised controlled clinical trial. Br J Ophthalmol. 2016;100:949–55.
Banerjee PJ, Cornelius VR, Phillips R, Lo JW, Bunce C, Kelly J, et al. Adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): study protocol for a phase III, multi-centre, double-masked randomised controlled trial. Trials. 2016;17:339.
Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159–65.
Di Lauro S, Kadhim MR, Charteris DG, Pastor JC. Classifications for proliferative vitreoretinopathy (PVR): an analysis of their use in publications over the last 15 years. J Ophthalmol. 2016;2016:7807596.
Wickham L, Bunce C, Wong D, Charteris DG. Retinal detachment repair by vitrectomy: simplified formulae to estimate the risk of failure. Br J Ophthalmol. 2011;95:1239–44.
Assi A, Khoueir Z, Helou C, Fakhoury H, Cherfan G. Intraocular application of Mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries. Eye. 2019;33:1261–70.
Acknowledgements
The research was funded by National Institute for Health Research Health Technology Assessment Programme, Moorfields Eye Hospital Special Trustees, Allergan Pharmaceuticals and Royal College of Surgeons of Edinburgh/Royal Blind and supported by the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology and the NIHR Moorfields Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Dr Geoffrey P Lewis supplied the images
Funding
The author has received grants for research on PVR from the following sources: National Institute for Health Research Health Technology Assessment Programme. Moorfields Eye Hospital Special Trustees. Allergan Pharmaceuticals. Royal College of Surgeons of Edinburgh/Royal Blind. NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This study was presented at the Cambridge Eye Symposium “Fibrosis and the Eye” 5–6 September 2019.
Rights and permissions
About this article
Cite this article
Charteris, D.G. Proliferative vitreoretinopathy: revised concepts of pathogenesis and adjunctive treatment. Eye 34, 241–245 (2020). https://doi.org/10.1038/s41433-019-0699-1
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-019-0699-1
This article is cited by
-
Leveraging AAV1-Rac1T17N to prevent experimental proliferative vitreoretinopathy
Journal of Translational Medicine (2025)
-
Proliferative vitreoretinopathy: an update on the current and emerging treatment options
Graefe's Archive for Clinical and Experimental Ophthalmology (2024)
-
Human Wharton’s Jelly Mesenchymal Stem Cell Secretome Modifies the Processes of Neuroprotection and Epithelial-Mesenchymal Transition in Retinal Pigment Epithelium at Transcriptional Level
Molecular Biology Reports (2023)
-
Large inferior retinectomies for proliferative vitreoretinopathy in silicone oil-filled eyes
International Journal of Retina and Vitreous (2022)
-
A bio-functional polymer that prevents retinal scarring through modulation of NRF2 signalling pathway
Nature Communications (2022)
